Zhejiang Hisun Pharmaceutical (600267.SH): Haibomai atorvastatin calcium tablets received drug clinical trial approval.

Zhejiang Hisun Pharmaceutical (600267.SH) announced that its wholly-owned subsidiary Hanhui Pharmaceutical Co., Ltd. (hereinafter referred to as "Hanhui Pharmaceutical") recently received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration (hereinafter referred to as the "NMPA") for Habo Maibo Atorvastatin Calcium Tablets (10mg/20mg). The indications for which Habo Maibo Atorvastatin Calcium Tablets are intended are for the treatment of adult patients with primary hypercholesterolemia or mixed dyslipidemia who have not achieved target levels of low-density lipoprotein cholesterol (LDL-C) with dietary control alone, and are in need of statin therapy.